SAN DIEGO / Nov 07, 2025 / Business Wire / Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in November.
UBS Global Healthcare Conference | ||
Date / Time: | November 10th | |
Format: | 1x1’s | |
Location: | Palm Beach, FL | |
Guggenheim Securities Healthcare Innovation Conference | ||
Date / Time: | November 11th, at 10:00 AM ET | |
Format: | Presentation & 1x1’s | |
Location: | Boston, MA | |
Webcast Link: | ||
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
| Last Trade: | US$3.14 |
| Daily Change: | -0.20 -5.99 |
| Daily Volume: | 5,139,100 |
| Market Cap: | US$726.780M |
November 05, 2025 September 25, 2025 September 22, 2025 August 29, 2025 August 05, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
